Background Metastatic soft tissue sarcoma not amenable to curative surgery has a dismal prognosis Aggressive treatment with anthracychnes and lfosfamide represents the current therapeutic mainstay in these patients, most of whom succumb to relapses. Thus, the efficacy of subsequent therapeutic approaches has to be weighed against toxicity caused by palliative treatment.
Introduction
Locally advanced or metastatic soft tissue sarcoma represents an incurable disease in the majority of patients not amenable to surgery with a curative intent or potentially curative innovative therapeutic approaches such as isolated limb perfusion [1] [2] [3] . However, in an attempt to prolong survival, preserve organ function and to palliate symptoms, chemotherapy and radiation therapy continue to constitute reasonable approaches Anthracyclines such as doxorubictn, either as single agents or in combination with ifosfamide, represent the standard chemotherapeutic armamentarium for the palliative treatment of soft tissue sarcomas. The combination and dose escalation of doxorubicin and ifosfamide or the addition of less active substances such as dacarbazine, cyclophosphamide, dactinomycin and vincristine has increased response rates, but also incurred toxicity. A benefit of combination chemotherapy or dose-escalated cytotoxic treatment in terms of overall survival, however, has only been demonstrated for patients with uterine sarcomas or in patients achieving a complete response to standard treatment, respectively [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
However, due to the aggressive nature of the disease, response rates of anthracycline-or lfosfamide-based combination chemotherapy remain below 60% and despite multimodality therapy the median survival after initial diagnosis of metastatic disease only approximates one year [16] . Thus, virtually all patients responsive to initial treatment eventually relapse making sustained remissions an exceedingly rare event.
Despite a plenitude of well conducted randomized clinical trials evaluating first line treatment for locally advanced or metastatic soft tissue sarcoma, data on appropriate second-and third-line treatment following persistence or progression of disease are scarce: Treatment with high-dose ifosfamide, alone or in combination with etoposide, has resulted in response rates of up to 39% in patients refractory to anthracychnes and standard-dose ifosfamide [17] [18] [19] Similar response rates have been reported with the use of doxorubicin in patients progressing after first-line treatment with highdose ifosfamide [20] .
In contrast, the role of salvage treatment in patients with locally advanced or metastatic disease refractory to standard treatment with anthracyclines and lfosfamide in terms of overall survival remains to be defined, yet Since conventional first-or second-line treatment for advanced soft tissue sarcomas is rather aggressive and causes considerable treatment-related morbidity, toxiclty of subsequent treatment becomes a major concern. Therefore, toxicity and tolerability of treatment influencing quality of life have to be taken into account and weighed against the likelihood of mostly transient remissions achieved by cytotoxic treatment. Within this context, several antineoplastic agents have recently been shown to exert moderate activity in pretreated patients: The use of high-dose dacarbazine, gemcitabine, oral trofosfamide and paclitaxel has resulted in partial responses and disease stabilization in 6%-18% and 33%-53% of patients, respectively, allowing for a median PFS and median OAS of 2-6 months and 8-10 months, respectively [21] [22] [23] [24] [25] [26] . Although similar response rates have been described with the use of liposomal encapsulated doxorubicin in pretreated patients [27] , these data will have to be confirmed in larger series due to the lack of efficacy of the substance observed in firstline treatment of advanced soft tissue sarcoma [28, 29] . Raltitrexed and oral etoposide, however, were found to be less active in this clinical setting [30, 31] .
The increased understanding of the molecular basis of drug resistance mechanisms and the observed nonoverlapping resistance mechanisms of anthracyclines and taxanes in patients with other malignant entities such as metastatic breast cancer [32] have been translated successfully into the preclmical evaluation of the efficacy of taxanes in anthracycline-resistant soft tissue sarcomas [33] Based upon a phase II study demonstrating moderate antitumoral efficacy of docetaxel as first-line treatment in patients with advanced soft tissue sarcoma [34] and on our previous results with docetaxel in patients refractory to standard treatment [35] , we conducted the present trial to evaluate the efficacy of docetaxel in symptomatic patients with locally advanced or metastatic soft tissue sarcomas heavily pretreated with anthracycline-and ifosfamide-containing regimens in terms of response rate (RR), PFS, OAS and qualitative as well as quantitative toxicity.
Patients and methods
The present trial for cytotoxic treatment of anthracycline-and lfosfamide-resistdnt locally advanced or metastatic soft tissue sarcoma with docetaxel was initiated in March 1997 and conducted according to the declaration of Helsinki at the University Hospital of Vienna, Austria Inclusion criteria All patients had histologically verified locally advanced or metastatic soft tissue sarcoma not amenable to surgery with curative intent and radiologically documented tumor progression bidimensionally measurable by CTor MRI scan within the last two weeks An interval of at least four weeks was required between completion of prior chemotherapy and start of docetaxel treatment Further inclusion criteria were WHO performance status < 3 (Karnofsky index ^ 40%), age 19 to 79 years, life expectancy > 12 weeks and a signed patient consent to participate in the study
Exclusion criteria
Exclusion criteria consisted of preceding cumulative anthracycline and lfosfamide dosage < 120 mg/m 2 and < 18 g/m 2 , respectively, inadequate hematologic function (as defined by white blood cells <20 x 1O 9 /1, absolute neutrophil count (ANC) < 1.0 x IO 9 /l, platelets < 50 x 10 9 /l), second malignancy with the exception of in situ cervical cancer or adequately treated basal cell or squamous cell carcinoma of the skin, history of atnal or ventricular arrhythmias and/or history of congestive heart failure (unless medically controlled), history of clinical and electrocardiographically documented myocardial infarction within the last two years and preexisting motor or sensory neurotoxjcity > grade 1 according to WHO criteria (consistent with moderate or severe paresthesia and/or objective weakness with or without functional impairment) Furthermore, patients with active infection or any other serious underlying medical condition, which would impair the ability of the patient to receive cytotoxic treatment, altered mental status that would prohibit the understanding and giving of informed consent, pregnant or breast feeding patients and finally patients with severe hepatic or renal dysfunction (bilirubin > 2 0 x upper limits of normal or transaminases J30 x upper limits of normal, creatinine clearance < 30 ml/min) were ineligible
Cytotoxic therapy

Dose and schedule
Docetaxel (100 mg/m 2 ) was given as a one-hour continuous intravenous infusion on day 1 of a 21-day-cycle Dosage modifications in case of docetaxel-induced hematologic toxicity WHO grade 4, febrile neutropema and non-hematologic toxicities ^ WHO grade 3 in previous cycles docetaxel dosage was reduced to 40 mg/m and administered weekly [36] Patients with inadequate bone marrow reserve (pretherapeutic ANC < 2 x 1O 9 /I or platelets < 75,000 x 1O 9 /1) were assigned to receive 40 mg/m 2 docetaxel in a weekly schedule If ANC on the day of scheduled treatment was below I 5 x 10 9 /l, treatment was withheld until resolution of neutropema, patients with delayed (>3 weeks) recovery from neutropema went off study
Supportive therapy
Antianaphylactic drug therapy administered concomitantly with docetaxel consisted of 8 mg dexamethasone twice daily orally for three days beginning one day prior to chemotherapy Standard antiemetic medication consisted of 5-HT 3 -antagonists on days 1 to 5 and, if needed, metoclopramide Hematopoietic growth factors erythropoietin (10,000 units, 3x/week until resolution of anemia) and filgrastim (30 x 10 6 units/day for five consecutive days) were administered subcutaneously in case of hematologic toxicities grades 2 and 4, respectively Antibiotics (piperacillin, ciprofloxacm) were administered in case of documented infection and/or febrile neutropema Packed red blood cells and platelets were transfused in case of > grade 3 anemia or hemorrhage and grade 4 thrombocytopenia, respectively Adequate pain control by non-steroidal and opioid analgesics was a prerequisite for study entry and analgesic dosage was adjusted throughout treatment as required
Evaluation of patients
Baseline evaluation included chest X-ray or CT scan, ultrasound or CT/MRI scan of the abdomen, bone scan and cardiac ultrasound as well as a complete blood cell count and blood chemistry Tumor measurement (baseline and response evaluation, see inclusion criteria) was carried with CT or MRI scan every alternate cycle or after each cumulative docetaxel dosage > 200 mg/m 2 for patients switched on the weekly schedule Previously irradiated lesions were considered ineligible for response assessment Identical methods were used for evaluation at baseline and for determination of response Hematologic and nonhematologic toxicities according to WHO criteria were assessed weekly
Duration of therapy
In case of complete remission (CR), two additional chemotherapy cycles were administered In case of stable disease (SD) or partial remission (PR), a total of six cycles were given Documented progression of disease according to WHO criteria resulted in discontinuation of the treatment protocol
Statistical analysis
Data are presented as mean ± standard deviation and median (range), respectively. Statistical significance was assessed using the log-rank test (progression free survival and overall survival) performed with the BMDP-PC program package
Results
This analysis covers the period between March 1997 and August 2000 during which patients with anthracychneand ifosfamide resistant locally advanced or metastatic soft tissue sarcoma were enrolled to receive docetaxel as rescue medication. Patients' characteristics are shown in Table 1 . Overall, 27 heavily pretreated symptomatic patients with a median age of 52 4 (range: 25.4 to 76.4) years with histologically verified locally advanced and/ or metastatic soft tissue sarcoma not amenable to surgery with curative intent were enrolled Pretreatment characteristics (summarized in Table 2) Before enrollment, all patients had progressed during or within three months after both doxorubicin-and ifosfamide-based chemotherapeutic regimens. In this cohort of 27 patients, 20 patients had initially presented with localized and surgically resectable disease, two patients presented with surgically incurable locally advanced sarcoma and the remaining five patients presented with surgically incurable metastatic disease at the time of diagnosis. Out of the 20 patients in whom the primary tumor had been resected with curative intent, 10 patients had received six cycles of adjuvant MAID chemotherapy consisting of ifosfamide and MESNA 6,0 g/m 2 and dacarbazine 800 mg/m 2 on days 1 to 4, doxorubicin 25 mg/m 2 on days 1 + 2, filgrastim 30 x 10 6 units/day on days 5-13, ql4d, three patients had received neoadjuvant chemoradiotherapy (30 Gy concomitantly with four cycles of ifosfamide and MESNA 6,0 g/m 2 and dacarbazine 800 mg/m 2 on days 1-4, ql4d) followed by five cycles of adjuvant MAID chemotherapy, one patient had received four cycles of doxorubicin (60 mg/m 2 on day 1, q21d) as adjuvant treatment, whereas five patients had received adjuvant radiotherapy only and one patient Abbreviations mos -months, SD -standard deviation had received no adjuvant treatment. Two patients presenting with locally advanced disease had rapidly progressed subsequently to three cycles of EVAIA (as described in [37]) followed by radiotherapy (30 Gy) or two cycles of MAID, respectively. First-line treatment for metastatic disease included high dose ifosfamide (12.5 g/m 2 on days 1 to 5, q28d) in seven patients, MAID in six patients, ifosfamide (5 g/m 2 ) and etoposide (500 mg/m 2 on days 1 to 5) administered concomitantly with radiotherapy in one patient, single-agent doxorubicin (60 mg/m 2 on day 1, q21d) in two patients, epirubicin (120 mg/m 2 on days 1 to 2) and ifosfamide (9 g/m 2 on days 1 to 5, q21d) in five patients, doxorubicin (50 mg/m 2 on days 1 to 2) and ifosfamide (7.5 g/m 2 on days 1 to 5, q21d) in three patients and docetaxel in two patients, both of which had developed metastatic disease within three months after the completion of adjuvant treatment by an anthracycline-and ifosfamide-containing chemo- 
Abbreviations PR -partial response; SD -stable disease, PD -progressive disease, MAID -mesna, adriamycin, ifosfamide, dacarbazine, D -docetaxel, HD-I -high dose ifosfamide, A -adriamycin, El -epirubicin, ifosfamide, I/VP-16 -ifosfamide, etoposide, M -mitoxanthrone (lntrapentoneal), AI -adriamycin, ifosfamide, 1F-DIC -ifosfamide, dacarbazine, EVAIA -etoposide, vincnstin, adnamycin, ifosfamide, mesna, actinomycin D, G -gemcitabine therapeutic regimen Second-line treatment for metastatic disease included MAID in one patient, high-dose ifosfamide in four patients, ifosfamide (4 5 g/m 2 ) and etoposide (600 mg/m 2 on days 1 to 3, q21d) in two patients, ifosfamide (4 5 g/m 2 on days 1 to 3) with mtrapentoneal mitoxantrone (20 mg on day 1, q21d) in one patient and docetaxel in 17 patients Third-line treatment included doxorubicin (two patients), high-dose ifosfamide (one patient), doxorubicin and intraperitoneal mitoxantrone (50 mg/m 2 and 20 mg, respectively on day 1, q21d) in one patient and docetaxel in four patients. Three consecutive patients received docetaxel as fourth-line treatment for metastatic soft tissue sarcoma and one patient received docetaxel as fifth-line treatment after failure of fourth-line treatment with intrapentoneal mitoxantrone.
Overall, no objective responses had been noted upon previous anthracyclme-or ifosfamide-based chemotherapy in any of the patients Before initiation of treatment with docetaxel, mean (± standard deviation) cumulatively delivered doxorubicin dose was 287 6 ± 112.6 mg/m 2 , mean cumulatively administered ifosfamide dose was 62.0 ± 28.6 g/m 2 .
Administered dosages of docetaxel
Overall, 106 cycles (80% at the scheduled 100 mg/m 2 dose level) of docetaxel were administered. Twenty-one patients received all cycles at the assigned 100 mg/m 2 dose in a three-weekly schedule, whereas the remainder of dosages was administered at a weekly 40 mg/m 2 schedule Two patients were scheduled to receive 40 mg/m 2 docetaxel in a weekly schedule due to inadequate bone marrow reserve Four patients were switched to the weekly schedule due to toxicity: aggravation of primarily underlying heart disease (n -1), tumor lysis syndrome (n = 1), WHO grade 4 leukopenia and anemia (n = 1), and WHO grade 3 diarrhea (n -1). At the reduced dose level, all but one patient tolerated treatment. Overall, 25 patients were treated on an outpatient basis, two patients were hospitalized.
Toxicity profile
Anemia grades 1 and 2 occurred in 18 (67%) patients, anemia grade 3 in 1 (4%) patient, with 1 (4%) patient requiring red blood cell transfusion. Leukopenia grades 1 or 2 occurred in 7 (26%), and grades 3 or 4 in 10 (37%) patients requiring treatment with filgrastim in 1 (4%) and hospitalization for the application of filgrastim and antibiotic treatment due to febrile neutropema in another 2 (7%) patients. One (4%) patient on docetaxel 100 mg/m 2 developed excessive tumor cell lysis, grade 2 elevation of hepatic and pancreatic enzymes and mtratumoral WHO grade 3 haemorrhage requiring transfusion of six units of packed blood cells Only one other case (4%) of grade 2 elevation of liver enzymes, one case (4%) of grade 1 elevation of bilirubin and one case (4%) of grade 2 thrombocytopenia were noted, whereas polyneuropathy was more common with grades 1 and 2 occurring in 5 (19%) and 2 (7%) patients, respectively. Trophic nail changes and onycholysis were noted in 1 (4%) and 2 (7%) patients, respectively, whereas 3 (11%) patients experienced fluid retention treated with oral spironolactone. Oral mucositis and diarrhea WHO grades 3 were noted in 1 (4%) patient, each. Grade 1 and 2 nausea requiring additional treatment with metoclopramide were present in 3 (11%) and 4 (15%) patients. Another (4%) patient experienced repeated exacerbation of underlying NYHA III coronary heart disease and, therefore, refused further treatment despite having achieved a partial response. Alopecia was preexistent in 19 (70%) of patients and grade 3 alopecia was found in all patients following treatment with docetaxel An overview of toxicity profile is given in Table 2 .
Clinical responses
No complete responses were noted Out of 27 patients, 4 (15%) achieved PR including 2 patients at the scheduled 100 mg/m 2 dose level and 2 patients switched to the weekly 40 mg/m 2 schedule due to toxicity. Another 4 (15%) patients including 1 patient at the weekly 40 mg/m 2 schedule experienced SD and 19 (70%) progressed. Objective responses were found irrespective of the number of preceding therapeutic regimens and preceding cumulative doxorubicin or lfosfamide dosage, respectively, and occurred in patients with epitheloid sarcoma, synovial sarcoma, leiomyosarcoma and inflammatory myofibroblastic tumor, respectively Two patients who achieved PRs discontinued treatment despite being switched to a weekly schedule of docetaxel after cycles 2 and 3, respectively, due to aggravation of underlying heart disease and for personal reasons, respectively. The first patient died two months later from sudden cardiac arrest, but a high resolution thoracic CT scan performed at that time confirmed that he was in ongoing remission. The other patient was compliant to follow-up and successfully reinduced with docetaxel upon renewed progression which occurred 8.2 months later (see below).
Progression-free survival (PFS) and overall survival (OAS)
At the time of evaluation in January 2001 median PFS for all patients was 2.4 (range: 0.9-23.9, 95% confidence interval (95% CI): 3.0-7 1) months After a median observation period of 21.0 (range: 4 to 44.4) months median OAS for all patients was 7.7 (range 1 0-44.3, 95% CI: 7.3-17.1) months with 10 (37%) patients still being alive at the time of analysis In patients with PR or SD median OAS was 21 1 (range: 4.7-44.3, 95% CI-8 7-35 6) months vs. 6.5 (range: 1.0-30 9, 95% CI: 4.4-11.6) months in patients with PD (P < 0.02). PFS and OAS curves are shown in Figure 1 .
Three patients who initially achieved PR (one patient) and SD (two patients), respectively, following treatment with docetaxel, were successfully reinduced with docetaxel upon renewed progression which occurred 8.2, 6 8 and 13.4 months later. These patients experienced PR (one patient) which lasted 7.2+ months and further SD (two patients) which lasted 9.4 and 4.0+ months, respectively.
No correlation between RR, OAS and PFS and known prognostic factors for the outcome of metastatic soft tissue sarcoma [38] including age, performance status, histology, histopathologic grading, the presence of visceral metastases and interval between the initial diagnosis and the occurrence of metastases was observed
Discussion
In the present study we report moderate efficacy of docetaxel administered as salvage treatment in patients refractory to treatment with anthracyclines and ifosfamide Although a plenitude of prognostic factors that adversely affect response to treatment and OAS was observed in our patient cohort, including old age, unfavorable histology, presence of liver metastases, short relapse-free interval [38] and, possibly, failure of previous treatment, 15% of patients achieved sustained responses or disease stabilization, respectively. In addition, upon renewed progression reinduction treatment with docetaxel was successful in patients initially responsive to docetaxel Recently published studies evaluating the efficacy of docetaxel in patients with advanced soft tissue sarcoma have produced controversial results: In two phase II studies, a modest efficacy of docetaxel has been found following failure anthracyclines in metastatic soft tissue sarcoma. Response rates were 3%-17% and disease stabilization occurred in approximately 40% of patients. In addition, time to progression (1.3-3 5 months) and overall survival (6-12 months) were relatively short [39, 
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Figure I Progression free survival (PFS) and overall survival (OAS) in patients receiving docetaxel after failure of anthracychnes and ifosfamide 40]. A recently published well-conducted randomized phase II -III crossover study comparing the efficacy of docetaxel and doxorubicin in the first-and second-line setting for metastatic soft tissue sarcoma was closed prematurely because no objective responses were observed in both, 42 patients assigned to first-line treatment with docetaxel and 16 patients receiving docetaxel as second-line treatment after failure of doxorubicin [41] . Albeit progression-free survival differed significantly between treatment groups (5.6 vs. 1.6 months), this did not result in a significant difference in overall survival (12.4 vs. 9.8 months) -probably due to the relatively high rate of disease stabilization in patients receiving docetaxel as first and second line treatment of 44% and 31%, respectively.
In the present study we demonstrate that after a relatively long median follow up of 21 0 months, patients with heavily pretreated advanced soft tissue sarcoma achieving a partial response or disease stabilization subsequently to treatment with docetaxel experience a significant and continuing advantage in overall survival as compared to patients progressing despite treatment (21 1 vs. 6.5 months, P < 0.02) Thus, alluding to our present understanding on the influence of antineoplastic treatment upon the course of malignant disorders [42], our ability to identify patients most likely to benefit from salvage treatment with docetaxel in terms of overall survival -even in the absence of objective responsesmay define the further role of docetaxel and other cytotoxic agents as salvage medication in heavily pretreated patients with advanced soft tissue sarcomas. Within this context, the variable pharmakokinetics of docetaxel observed in patients with soft tissue sarcomas [43] , molecular characteristics of the individual tumor and mechanisms of resistance to taxanes [44] as well as differences in proliferation rates affecting sensitivity to chemotherapy [45] have to be taken into account.
Alluding to evidence derived from previous clinical trials, we agree with the authors of previous trails that due to their proven efficacy and tolerabihty, anthracychne-and lfosfamide-based chemotherapeutic regimens continue to be the therapeutic mainstay in patients with advanced soft tissue sarcomas, whereas the role of docetaxel in soft tissue sarcomas is restricted to its use as rescue medication Whether a combination therapy of docetaxel with ifosfamide [46] or anthracychnes [47, 48] as first-or second-line treatment for metastatic soft tissue sarcoma will improve survival in certain patients remains to be determined in future clinical trials. (1) 
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